145 related articles for article (PubMed ID: 37227921)
1. Successful treatment of urticarial vasculitis with omalizumab in children: a case series.
Wang S; Fu L; Xiang X; Zhang B; Ma L; Xing H
Clin Exp Dermatol; 2023 Sep; 48(10):1145-1148. PubMed ID: 37227921
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review.
Rattananukrom T; Svetvilas P; Chanprapaph K
Asian Pac J Allergy Immunol; 2020 Dec; 38(4):286-289. PubMed ID: 30660172
[TBL] [Abstract][Full Text] [Related]
4. Treatment of urticarial vasculitis: A systematic review.
Kolkhir P; Grakhova M; Bonnekoh H; Krause K; Maurer M
J Allergy Clin Immunol; 2019 Feb; 143(2):458-466. PubMed ID: 30268388
[TBL] [Abstract][Full Text] [Related]
5. Urticarial Vasculitis Differs From Chronic Spontaneous Urticaria in Time to Diagnosis, Clinical Presentation, and Need for Anti-Inflammatory Treatment: An International Prospective UCARE Study.
Bonnekoh H; Jelden-Thurm J; Allenova A; Chen Y; Cherrez-Ojeda I; Danilycheva I; Dorofeeva I; Jardim Criado RF; Criado PR; Gelincik Akkor A; Hawro T; Kocatürk E; Khoshkhui M; Metz M; Nasr I; Steć M; Zhao Z; Aulenbacher F; Salameh P; Altrichter S; Gonçalo M; Gimenez-Arnau A; Maurer M; Krause K; Kolkhir P
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2900-2910.e21. PubMed ID: 37364667
[TBL] [Abstract][Full Text] [Related]
6. Cold urticarial vasculitis successfully treated with omalizumab.
Ayén-Rodríguez A; Llamas-Molina JM; Gálvez-Moreno M; Ruiz-Villaverde R
Int J Dermatol; 2023 Feb; 62(2):e77-e78. PubMed ID: 35167707
[No Abstract] [Full Text] [Related]
7. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
Skander D; Allenova A; Maurer M; Kolkhir P
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
[No Abstract] [Full Text] [Related]
8. Urticarial Vasculitis Successfully Treated With Omalizumab.
Ermertcan AT; Aktaş A; Öztürk F; Temiz P
Cutis; 2021 May; 107(5):E19-E21. PubMed ID: 34288864
[No Abstract] [Full Text] [Related]
9. [Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases].
Díez LS; Tamayo LM; Cardona R
Biomedica; 2013; 33(4):503-12. PubMed ID: 24652205
[TBL] [Abstract][Full Text] [Related]
10. Use of omalizumab in the treatment of hypocomplementemic urticarial vasculitis.
Navarro-Navarro I; Jiménez-Gallo D; Villegas-Romero I; Linares-Barrios M
Dermatol Ther; 2020 Mar; 33(2):e13237. PubMed ID: 32012397
[No Abstract] [Full Text] [Related]
11. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of reserpine as "add-on therapy" to antihistamines in patients with recalcitrant chronic idiopathic urticaria and urticarial vasculitis.
Demitsu T; Yoneda K; Kakurai M; Sasaki K; Hiratsuka Y; Azuma R; Yamada T; Umemoto N
J Dermatol; 2010 Sep; 37(9):827-9. PubMed ID: 20883370
[No Abstract] [Full Text] [Related]
13. Long-Term Efficacy and Safety of Omalizumab Monotherapy in a Patient With Normocomplementemic Urticarial Vasculitis.
Abuzakouk M; Ghorab O; Namas R; Maurer M
J Drugs Dermatol; 2022 Oct; 21(10):1124-1126. PubMed ID: 36219045
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
Front Immunol; 2021; 12():635069. PubMed ID: 33737936
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of omalizumab in two cases of normocomplementemic urticarial vasculitis due to perivascular mast cell infiltration.
Ito T; Maeda T; Egusa C; Abe N; Seshimo H; Okubo Y; Harada K
Allergol Int; 2021 Apr; 70(2):269-270. PubMed ID: 33183981
[No Abstract] [Full Text] [Related]
16. A Case of Hypocomplementemic Urticarial Vasculitis Syndrome Successfully Treated With Omalizumab.
Nucera E; Basta F; Buonomo A; Mezzacappa S; Margiotta DP; Antonelli Incalzi R; Schiavino D
J Investig Allergol Clin Immunol; 2017; 27(6):382-384. PubMed ID: 29199964
[No Abstract] [Full Text] [Related]
17. Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab.
Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
Clin Exp Allergy; 2021 Dec; 51(12):1648-1652. PubMed ID: 34519110
[No Abstract] [Full Text] [Related]
18. COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab.
Baldallo C; León Román JC; Serón D; Agraz I; Solans R; Ramos N; Soler MJ
Nefrologia (Engl Ed); 2021; 41(3):354-356. PubMed ID: 32826086
[No Abstract] [Full Text] [Related]
19. Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome.
Aurich S; Simon JC; Treudler R
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e395-e397. PubMed ID: 28273376
[No Abstract] [Full Text] [Related]
20. The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months' Evolution and Prior Immunosuppressive Treatment.
Cubiró X; Spertino J; Rozas-Muñoz E; Serra-Baldrich E; Puig L
Actas Dermosifiliogr (Engl Ed); 2019 May; 110(4):289-296. PubMed ID: 30360885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
